Additional cost pressures loom from potential tariffs on imported drugs, while biosimilar competition is a longer-term certaintysemaglutide patents are expected to expire in 203132, with tirzepatide protections extending into 2036 and beyond
Tremfya (guselkumab) Disease area(s): Immunology Manufacturer(s): Johnson & Johnson 2024 Sales (USD): $3.67 billion Why it sold so well: J&Js IL-23 inhibitor Tremfya experienced significant sales growth last year with $3.67 billion in total sales, an increase of 16.6% from 2023
Addiction treatment approaches must be carefully tailored
10.1080/19382014.2019.1587976 76 PerryR
CGRP released from cutaneous trigeminal nerve fibers and acts on surrounding Schwann cells, perpetuating cutaneous allodynia through a cyclic AMP-dependent mechanism that generates NO in endosomes (31)
Kathleen Valenton, board-certified physician and Chief Medical Officer at Lemme, who points out that most people who stop taking their meds regain weight
